在阿尔茨海默氏病中,SMOC2促进微质活动和神经炎症
1Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Journal of Alzheimer's disease : JAD
|January 10, 2025
概括
分泌的模块化结合蛋白2 (SMOC2) 通过调节微质功能来影响阿尔茨海默病 (AD) 病理学. 向SMOC2可能通过增强微质细胞化和减少粉样β积累,为AD提供一种新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特征是认知能力下降和粉样β (Aβ) 积累.
- 微质细胞在阿尔茨海默氏症的发病过程中起着至关重要的作用,它们的功能越来越被认为是治疗点.
- 分泌的模块化结合蛋白2 (SMOC2) 已与炎症和纤维化过程有关,这表明它可能在AD中发挥作用.
研究的目的:
- 在阿尔茨海默病病理学背景下,研究SMOC2在微质细胞中的作用.
- 确定SMOC2调节对微质活动,细胞和炎症反应的影响.
主要方法:
- 使用过度表达和干扰载体来操纵Aβ处理的微质细胞中的SMOC2水平.
- 使用CCK8试验和流细胞计量,量化了细胞活性和细胞化.
- 对SMOC2,炎症标记物 (TNF-α,IL-1β) 和微质偏振标记物 (CD163,CD206) 的基因和蛋白质表达水平使用qPCR,西部斑,ELISA和免疫光分析.
主要成果:
- Aβ治疗损害了微质活动和细胞形成,而SMOC2干扰显著增强了这些功能.
- 过度SMOC2表达增加了Aβ水平,并促进了促炎反应 (增加了TNF-α,IL-1β,p-NF-κB/NF-κB),同时降低了抗炎标志物 (TGF-β1,CD163,CD206).
- 相反,SMOC2干扰降低了Aβ水平,并调节了炎症和极化标志物,这表明SMOC2具有保护作用.
结论:
- 在AD的背景下,SMOC2显著影响微质细胞活动,细胞化和极化.
- 这些发现表明,SMOC2可能通过TGF-β1/NF-κB信号通路发挥其作用.
- 调节SMOC2通过向微质功能障碍,为阿尔茨海默病提供了潜在的治疗途径.
相关概念视频
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...


